Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Dabomb Protein Biotech's 3-Year RORE % for the quarter that ended in Mar. 2026 was 8.71%.
The industry rank for Dabomb Protein Biotech's 3-Year RORE % or its related term are showing as below:
ROCO:6578's 3-Year RORE % is ranked better than 52.87% of 1829
companies
in the Consumer Packaged Goods industry
Industry Median: 6.02
vs ROCO:6578: 8.71
Dabomb Protein Biotech (ROCO:6578) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Dabomb Protein Biotech 3-Year RORE % Related Terms
Dabomb Protein Biotech 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech 3-Year RORE % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Dabomb Protein Biotech (ROCO:6578) has a 3-Year RORE % of 8.71 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Dabomb Protein Biotech and its competitors. According to the industry distribution chart, Dabomb Protein Biotech ranks #862 out of 1829 companies in the Consumer Packaged Goods industry, placing it in the top 47.1%.
Is Dabomb Protein Biotech's 3-Year RORE % too high?
Dabomb Protein Biotech's current 3-Year RORE % is 8.71. The Consumer Packaged Goods industry median 3-Year RORE % is 6.02. Dabomb Protein Biotech's value of 8.71 is 44.7% above this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #862 out of 1829 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Dabomb Protein Biotech has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's 3-Year RORE % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #862 out of 1829 companies for 3-Year RORE %. This puts Dabomb Protein Biotech in the upper half of its industry. The industry median 3-Year RORE % is 6.02. Dabomb Protein Biotech's value of 8.71 is 44.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Consumer Packaged Goods company?
The median 3-Year RORE % among Consumer Packaged Goods companies is 6.02, based on 1,829 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current 3-Year RORE % of 8.71 is 44.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median 3-Year RORE % is 6.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current 3-Year RORE % is 8.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$16.62, compared to a current price of NT$16.10 — trading 3.1% below its estimated fair value. The current 3-Year RORE % is 8.71 and 44.7% above the Consumer Packaged Goods industry median of 6.02. Dabomb Protein Biotech's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current 3-Year RORE % is 8.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be undervalued.
The current stock price of NT$16.10 is trading 3.1% below its estimated GF Value™ of NT$16.62.
GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.
Key valuation signals for ROCO:6578:
3-Year RORE %: 8.71
GF Value™: NT$16.62 vs. price of NT$16.10 (3.1% below fair value)
Industry Position: 44.7% above the Consumer Packaged Goods median (#862 of 1829)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
58GF Score
Get the complete analysis for ROCO:6578
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
